To the Editor We read the recent article by Warraich and colleagues1 with much interest. The authors concluded that despite the availability of generic atorvastatin, payers continue to pay substantial excess expenditures for Lipitor (Pfizer). Unfortunately, proprietary pharmaceutical industry rebates make it difficult to assess the validity of this conclusion.